Lantheus Holdings, Inc.the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better ...
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...
Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfoli...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentat...
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of d...
Scorpius Holdings, Inc. (OTC: SCPX), a biomanufacturing company dedicated to advancing therapeutic production capabilities, today announced a comprehensi...
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...
Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery...
Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organ...
Innovent Biologics, Inc. ("Innovent"), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for t...
Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell line developme...
IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small blood vessels. It is caused by ...
Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer therapeutics, announced new preclin...
© 2025 Biopharma Boardroom. All Rights Reserved.
